Luigi Celio Selected Research

Palonosetron (Aloxi)

1/2022	Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice.
10/2021	Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study.
3/2020	Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study.
1/2020	Every-other-day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: A randomized, controlled study from the "Rete Ematologica Pugliese".
12/2019	Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence.
12/2019	One-Day Versus Three-Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data-Based Meta-Analysis.
8/2018	Pro-netupitant/palonosetron (IV) for the treatment of radio-and-chemotherapy-induced nausea and vomiting.
1/2015	Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapy.
12/2014	Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy.
7/2014	Aprepitant versus dexamethasone for delayed emesis: what is the role of the 5-hydroxytryptamine type 3 receptor antagonist palonosetron?

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Luigi Celio Research Topics

Disease

27	Vomiting 01/2022 - 07/2008
26	Nausea 01/2022 - 07/2008
14	Breast Neoplasms (Breast Cancer) 01/2021 - 05/2003
13	Neoplasms (Cancer) 01/2022 - 12/2002
2	Stomach Neoplasms (Stomach Cancer) 01/2009 - 12/2002
1	Cholangiocarcinoma 07/2021
1	Diarrhea 03/2020
1	Lymphatic Metastasis 01/2020
1	Circulating Neoplastic Cells 01/2020
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2020
1	Neutropenia 01/2019
1	Colorectal Neoplasms (Colorectal Cancer) 01/2009
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2006
1	Adenocarcinoma 12/2002

Drug/Important Bio-Agent (IBA)

18	Palonosetron (Aloxi)FDA Link 01/2022 - 07/2008
17	Dexamethasone (Maxidex)FDA LinkGeneric 10/2021 - 07/2008
12	AntiemeticsIBA 01/2021 - 07/2008
6	AnthracyclinesIBA 01/2021 - 02/2013
6	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021 - 02/2013
4	netupitantIBA 01/2022 - 08/2018
4	Cisplatin (Platino)FDA LinkGeneric 10/2021 - 07/2008
4	Aprepitant (Emend)FDA Link 01/2020 - 07/2008
3	Carboplatin (JM8)FDA LinkGeneric 01/2021 - 01/2019
3	Thrombin FDA Link 01/2021 - 01/2020
3	Capecitabine (Xeloda)FDA Link 03/2020 - 04/2005
3	Hormones (Hormone)IBA 03/2020 - 05/2003
3	Olanzapine (Zyprexa)FDA Link 06/2019 - 01/2017
2	EmeticsIBA 10/2021 - 01/2017
2	Gemcitabine FDA Link 07/2021 - 01/2019
2	Pharmaceutical PreparationsIBA 07/2021 - 01/2020
2	Neurokinin-1 Receptor AntagonistsIBA 01/2021 - 07/2019
2	5-HT3 Serotonin Receptors (5 HT3 Receptor)IBA 01/2021 - 01/2020
2	Paclitaxel (Taxol)FDA LinkGeneric 06/2019 - 01/2013
2	Serotonin (5 Hydroxytryptamine)IBA 01/2017 - 07/2014
2	Toremifene (Fareston)FDA Link 06/2008 - 12/2004
1	Phosphotransferases (Kinase)IBA 07/2021
1	ON 01910IBA 07/2021
1	Radiation-Sensitizing AgentsIBA 07/2021
1	Vinorelbine (Navelbine)FDA LinkGeneric 03/2020
1	Transaminases (Aminotransferases)IBA 03/2020
1	AntithrombinsIBA 01/2020
1	Fibrinogen (Factor I)FDA Link 01/2020
1	Hemostatics (Antihemorrhagics)IBA 01/2020
1	Phenobarbital (Luminal)FDA Link 01/2020
1	Prothrombin (Factor II)IBA 01/2020
1	Epithelial Cell Adhesion MoleculeIBA 01/2020
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	fibrin fragment D (D-dimer)IBA 01/2020
1	Mechlorethamine (Nitrogen Mustard)FDA Link 01/2017
1	Streptozocin (Streptozotocin)FDA Link 01/2017
1	Metoclopramide (Reglan)FDA LinkGeneric 01/2017
1	Carmustine (FIVB)FDA Link 01/2017
1	Dacarbazine (DIC)FDA LinkGeneric 01/2017
1	Serotonin 5-HT3 Receptor AntagonistsIBA 10/2013
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2013
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2013
1	fosaprepitant FDA Link 01/2013
1	Irinotecan (Camptosar)FDA LinkGeneric 01/2009
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2009
1	Complementary DNA (cDNA)IBA 06/2008
1	Estrogen Receptor alphaIBA 06/2008
1	Estrogen ReceptorsIBA 06/2008
1	Estrogens (Estrogen)FDA Link 06/2008
1	Biological ProductsIBA 01/2006
1	Messenger RNA (mRNA)IBA 12/2004
1	Estrogen Receptor betaIBA 12/2004
1	Estrogen Receptor Modulators (Antiestrogen)IBA 12/2004
1	Aromatase InhibitorsIBA 05/2003
1	Interleukin-6 (Interleukin 6)IBA 05/2003
1	Letrozole (Femara)FDA LinkGeneric 05/2003
1	Aminoglutethimide (Cytadren)FDA Link 05/2003
1	Anastrozole (Arimidex)FDA LinkGeneric 05/2003
1	Insulin-Like PeptidesIBA 05/2003
1	exemestane (Aromasin)FDA Link 05/2003
1	Folic Acid AntagonistsIBA 12/2002
1	Pemetrexed (MTA)FDA Link 12/2002

Therapy/Procedure

28	Drug Therapy (Chemotherapy) 01/2022 - 12/2002
8	Therapeutics 01/2022 - 12/2002
1	Adjuvant Chemotherapy 01/2020
1	Induction Chemotherapy 01/2020
1	Radiotherapy 08/2018
1	Aftercare (After-Treatment) 12/2004